Telix Pharmaceuticals Ltd — Director's Dealing 2025

Mar 11, 2025

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity Telix Pharmaceuticals Limited ABN 85 616 620 369

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Dr Christian Behrenbruch
Date of last notice	27 February 2025

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or indirect interest	Direct interest
Nature of indirect interest(including registered holder)Note: Provide details of the circumstances giving rise to the relevantinterest.	N/A
Date of change	6 March 2025
No. of securities held prior to change	Direct Interest•553,298 fully paid ordinary shares (including400,000 American Depository Shares (eachrepresenting 1 ordinary share) in TelixPharmaceuticals Limited).•100,708 share options with an exercise price of$4.38 per option and an expiry date of 26January 2026. Options vest upon achievementof $100M in cumulative revenue from productsales. Options allotted following shareholderapproval at the AGM held 12 May 2021(TLXO009 - TLXAL).•139,672 Performance Share Appreciation Rights(notional exercise price $4.95) (TLXO012 -TLXAO) issued following shareholder approval atthe AGM held 18 May 2022.

• See chapter 19 for defined terms.

01/01/2011

Appendix 3Y Page 1

Appendix 3Y Change of Director’s Interest Notice

						•120,268 Performance Share Appreciation Rights(notional exercise price $6.90) (TLXO015 -	•120,268 Performance Share Appreciation Rights(notional exercise price $6.90) (TLXO015 -	•120,268 Performance Share Appreciation Rights(notional exercise price $6.90) (TLXO015 -	•120,268 Performance Share Appreciation Rights(notional exercise price $6.90) (TLXO015 -	•120,268 Performance Share Appreciation Rights(notional exercise price $6.90) (TLXO015 -
						TLXAO) issued following shareholder approval atthe AGM held 24 May 2023.•144,037 Performance Share Appreciation Rights(notional exercise price $11.94) (TLXO024 -TLXAO) issued following shareholder approval at
						the AGM held 22 May 2024.Indirect interest•20,675,000 fully paid ordinary shares (Elk RiverHoldings Pty Ltd as Trustee for The BehrenbruchFamily Trust).
		Class				Performance Share Appreciation Rights (notionalexercise price $4.95) (TLXO012 - TLXAO)
		Number acuired				Nil
		q
		N	mber disposed				46,558
		u
		Value/ConsiderationNote: If consideration is non-cash, provide details and estimatedvaluation				Nil
		No.	of securities held a	fter change			Direct Interest
						•553,298 fully paid ordinary shares (including400,000 American Depository Shares (each
						representing 1 ordinary share) in TelixPharmaceuticals Limited).

• See chapter 19 for defined terms.

01/01/2011

Appendix 3Y Page 2

Appendix 3Y Change of Director’s Interest Notice

	Nature of changeExample: on-market trade, off-market trade, exercise of options, issueof securities under dividend reinvestment plan, participation in buy-back	Lapse of Performance Share Appreciation Rights as aresult of testing and vesting of the 2022Performance Share Appreciation Rights grant.

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder(if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interestrelated prior to changeNote: Details are only required for a contract in relation to which theinterest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/ConsiderationNote: If consideration is non-cash, provide details and an estimatedvaluation	N/A
Interest after change	N/A

3 –[+] Closed period Part

Were the interests in the securities or contractsdetailed above traded during a+closed periodwhere prior written clearance was required?	No
If so, was prior written clearance provided toallow the trade to proceed during this period?	N/A
If prior written clearance was provided, on whatdate was this provided?	N/A

• See chapter 19 for defined terms.

01/01/2011

Appendix 3Y Page 3